Immune reconstitution in very advanced HIV patients treated with dolutegravir vs. darunavir-based triple antiretroviral therapy: the Advanz-4 randomized clinical trial


Por: Miro, JM, Torres, F, Manzardo, C, Bonfill, E, Curran, A, Domingo, P, Podzamczer, D, Paredes, R, Force, L, Falco, V, Gutierrez, M, Saumoy, M, Castelli, A, Inciarte, A, Rovira, C, Cruceta, A, Hurtado, C, Climent, N, Lozano, F and Plana, M

Publicada: 1 ene 2026 Ahead of Print: 1 dic 2025
Resumen:
Objectives: The aim of this trial was to compare the immune reconstitution, virologic response, and safety of dolutegravir (DTG) vs. darunavir (DRV) boosted-based antiretroviral (ART) regimens in very advanced HIV patients. Methods: Phase IV, randomized (1:1 ratio), open-label trial, including adult (>= 18 years) ART-na & iuml;ve HIV-1+ patients with CD4+ cell counts <100 cells/pL from nine hospitals in Spain. Participants were randomized to lamivudine (3TC)/abacavir (ABC)/DTG (DTG arm) and 3TC/ABC/DRV + ritonavir (DRV/r arm). Primary endpoint: change in the absolute CD4+ cell number at 48 weeks in the modified intention-to-treat population. Trial Registration: NCT02337322. Results: In total, 104 patients (86.5% male, median (interquartile range [IQR]) age 41.0 (31.5, 47.0) years) were recruited and randomized to DTG (n = 52) and DRV/r arms (n = 52). Baseline median (IQR) CD4+ cell counts were 39.5 (16.0, 72.9) and 29.0 (8.0, 60.0) cells/pL in the DTG and DRV/r arms. They significantly increased by median (IQR) 206.5 (154.4, 310.5) and 180.0 (89.4, 314.0) cells/pL, respectively (p 0.2549); 29 (55.8%) and 21 (42.9%) (p 0.2343) patients, respectively, reached >200 cells/pL. Of the patients, 41 (78.8%) and 31 (63.3%) (p 0.1229) in the DTG and DRV/r arms, respectively, achieved undetectable viral loads at 48 weeks; differences were significant at weeks 4 (p < 0.0001) and 12 (p 0.0009). Inflammation and bacterial translocation markers decreased more in the DTG arm, median (IQR)-8 (- 11,-4) vs.-5 (- 9,-3) pg/mL (p 0.0357) and-972 (- 1334,-508) vs.-544 (- 1128,-292) g/mL (p 0.0565), respectively, at 48 weeks. Discontinuation rates were higher in the DRV/r arm (3/52 (5.8%) vs. 9/51 (18.4%); p 0.0526). Conclusions: DTG/3TC/ABC is safe and efficacious in very advanced ART-na & iuml;ve HIV + patients, induced a faster virologic response, and was superior to the DRV/r regimen in reducing inflammation and bacterial translocation markers at 48 weeks. Miro JM, dlin Microbiol Infect 2026;32:169 (c) 2025 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Filiaciones:
Miro, JM:
 Univ Barcelona, Hosp Clin Fundacio Recerca Clin Barcelona, Inst Invest Biomed August Pi Sunyer FRCB IDIBAPS i, Infect Dis Serv, Barcelona, Spain

 Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Infecciosas CIB, Madrid, Spain

 Reial Acad Med Catalunya, Barcelona, Spain

Torres, F:
 Univ Autonoma Barcelona, Med Sch, Biostat Unit, Barcelona, Spain

 Hosp Clin IDIBAPS, Med Stat Core Facil, Barcelona, Spain

Manzardo, C:
 Univ Barcelona, Hosp Clin Fundacio Recerca Clin Barcelona, Inst Invest Biomed August Pi Sunyer FRCB IDIBAPS i, Infect Dis Serv, Barcelona, Spain

Bonfill, E:
 Hosp Clin Fundacio Recerca Clin Barcelona, Inst Invest Biomed August Pi Sunyer FRCB IDIBAPS i, Clin Trials Unit, Barcelona, Spain

Curran, A:
 Hosp Univ Vall dHebron, Vall dHebron Inst Recerca VHIR, Infect Dis Serv, Barcelona, Spain

Domingo, P:
 Hosp Univ Santa Creu i St Pau, HIV Unit, Barcelona, Spain

Podzamczer, D:
 Hosp Univ Bellvitge, Bellvitge Biomed Res Inst IDIBELL, Dept Infect Dis, HIV & Sexually Transmitted Dis STD Unit, LHospitalet de Llobregat, Barcelona, Spain

 Fight AIDS Fdn, Badalona, Spain

:
 Fight AIDS Fdn, Badalona, Spain

 Hosp Univ Germans Trias i Pujol, Infect Dis Serv, Badalona, Spain

Force, L:
 Hosp Univ Mataro, Internal Med Serv, Barcelona, Spain

Falco, V:
 Hosp Univ Vall dHebron, Vall dHebron Inst Recerca VHIR, Infect Dis Serv, Barcelona, Spain

Gutierrez, M:
 Hosp Univ Santa Creu i St Pau, HIV Unit, Barcelona, Spain

Saumoy, M:
 Hosp Univ Bellvitge, Bellvitge Biomed Res Inst IDIBELL, Dept Infect Dis, HIV & Sexually Transmitted Dis STD Unit, LHospitalet de Llobregat, Barcelona, Spain

Castelli, A:
 Univ Barcelona, Hosp Clin Fundacio Recerca Clin Barcelona, Inst Invest Biomed August Pi Sunyer FRCB IDIBAPS i, Infect Dis Serv, Barcelona, Spain

Inciarte, A:
 Univ Barcelona, Hosp Clin Fundacio Recerca Clin Barcelona, Inst Invest Biomed August Pi Sunyer FRCB IDIBAPS i, Infect Dis Serv, Barcelona, Spain

Rovira, C:
 Univ Barcelona, Hosp Clin Fundacio Recerca Clin Barcelona, Inst Invest Biomed August Pi Sunyer FRCB IDIBAPS i, Infect Dis Serv, Barcelona, Spain

Cruceta, A:
 Hosp Clin Fundacio Recerca Clin Barcelona, Inst Invest Biomed August Pi Sunyer FRCB IDIBAPS i, Clin Trials Unit, Barcelona, Spain

Hurtado, C:
 Univ Barcelona, Hosp Clin Fundacio Recerca Clin Barcelona, Inst Invest Biomed August Pi Sunyer FRCB IDIBAPS i, Infect Dis Serv, Barcelona, Spain

Climent, N:
 Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Infecciosas CIB, Madrid, Spain

 Univ Barcelona, Hosp Clin FRCB IDIBAPS, HIV AIDS Unit, Barcelona, Spain

Lozano, F:
 Hosp Clin Barcelona, Serv Immunol, Ctr Diagnost Biomed, Barcelona, Spain

 FRCB IDIBAPS, Immunoreceptors Innate & Adapt Immun, Barcelona, Spain

 Univ Barcelona, Dept Biomed, Barcelona, Spain

Plana, M:
 Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Infecciosas CIB, Madrid, Spain

 Univ Barcelona, Hosp Clin FRCB IDIBAPS, AIDS Res Grp, Barcelona, Spain
ISSN: 1198743X





CLINICAL MICROBIOLOGY AND INFECTION
Editorial
Elsevier Limited, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 32 Número: 1
Páginas: 169-176
WOS Id: 001650572000001
ID de PubMed: 41083105

MÉTRICAS